



# Performance Evaluation of the ADVIA Centaur Androstenedione Assay

Parker L,<sup>1</sup> Driscoll J,<sup>1</sup> Higgins C,<sup>1</sup> Stranz M,<sup>1</sup> Garvey K,<sup>1</sup> Donovan P,<sup>2</sup> Zhao Z,<sup>1</sup>  
Zheng YF,<sup>1</sup> Freeman J.<sup>1</sup>

[siemens-healthineers.com](https://www.siemens-healthineers.com)

Clinical  
Brief

1. Siemens Healthcare Diagnostics Inc., Newark, DE, U.S.  
2. Siemens Healthcare Diagnostics Inc., Walpole, MA, U.S.

# Performance Evaluation of the Androstenedione Assay

## Background

Androstenedione is a 19-carbon steroid that serves as a precursor for testosterone and estrone. It is primarily synthesized from dehydroepiandrosterone (DHEA) via 3 $\beta$ -hydroxysteroid dehydrogenase in the ovaries, testes, and adrenal glands.<sup>1-3</sup>


Androstenedione is most commonly used in conjunction with other steroid assays to evaluate the function of the adrenal glands and ovaries or testes and to determine the cause of symptoms of androgen excess.<sup>3-7</sup> It is also used in the monitoring of treatment for congenital adrenal hyperplasia.<sup>8,9</sup>

Hyperandrogenism can result from various disease states, including polycystic ovarian syndrome (PCOS), premature adrenarche, and congenital adrenal hyperplasia (CAH). The symptoms of androgen excess often include those of virilization, such as acne, hair loss, deepening of voice, and hirsutism. Androgen determination is used to differentiate benign conditions such as precocious puberty from those that are more serious, such as gonadal or adrenal tumors. It is also used to monitor treatment for patients with androgen excess, such as those with diagnosed CAH.<sup>5,10-12</sup>

The ADVIA Centaur® Androstenedione (ANDRO) Assay uses direct chemiluminescent technology to measure the concentration of androstenedione in human serum and plasma.

## Methods

### Principle of the assay



**Figure 1.** ADVIA Centaur ANDRO Assay format.

### Method comparison

A total of 129 native serum samples were evaluated using the ANDRO assay on the ADVIA Centaur XP Immunoassay System and LC-MS/MS (ARUP Laboratories, Salt Lake City, Utah; Quest Diagnostics, San Juan Capistrano, CA). Single-replicate data were plotted, and slope and intercept were determined using Passing-Bablok regression. The correlation coefficient (r) was determined using least squares regression.

### Specimen equivalence

A total of 63 native and spiked matched serum, EDTA, and lithium heparin plasma samples were evaluated using the ANDRO assay on the ADVIA Centaur XP system. Single-replicate data were plotted, and slope and intercept were determined using Passing-Bablok regression. Correlation coefficients (r) were determined using least squares regression.

### Precision

Bio-Rad LIQUICHEK Immunoassay Plus controls, calibrators, and patient samples distributed across the assay range were processed in replicates of two, twice a day, for 20 days using the ANDRO assay on the ADVIA Centaur XP system. Mean analyte values, repeatability, and within-lab precision were calculated for each sample, and 95% upper confidence limits were determined.

### Interference

Serum samples spiked with potential interferents and matched controls were processed in replicates of three using the ANDRO assay on the ADVIA Centaur XP system. Interference was calculated as the %difference between the mean test and control sample results, with respect to the mean control sample result:

$$\% \text{Interference} = 100 \times (\text{Mean}_{\text{Test}} - \text{Mean}_{\text{Control}}) / (\text{Mean}_{\text{Control}})$$

Biotin interference was determined by titrating increasing amounts of biotin into serum samples and plotting ANDRO recovery versus biotin concentration.

### Cross-reactivity

Serum samples spiked with potential cross-reactants and matched controls were processed in replicates of three using the ANDRO assay on the ADVIA Centaur XP system. Cross-reactivity was calculated as the %difference between the mean test and control sample results, with respect to the test compound concentration:

$$\% \text{Cross-reactivity} = 100 \times (\text{Mean}_{\text{Test}} - \text{Mean}_{\text{Control}}) / (\text{Concentration}_{\text{Test}})$$

### Calibration interval and onboard stability

Bio-Rad LIQUICHEK Immunoassay Plus controls, calibrators, and patient samples distributed across the measuring interval were processed using the ANDRO assay on the ADVIA Centaur XP system in minimum replicates of four over 12 test days (study duration: 36 days). A fresh reagent pack was loaded at each time point, and mean observed analyte results were calculated.


Calibration interval was determined by performing a linear regression of the recoveries (Y-axis) versus test day (X-axis). A linear regression of normalized onboard means (Y-axis) versus test day (X-axis) was then plotted. If the regression slope was statistically significant ( $p < 0.05$ ), the calibration interval for that sample was taken as the time at which the two-sided 90% confidence interval of the regression line intersected with the allowable drift-acceptance criterion. If the regression slope was not significant ( $p \geq 0.05$ ), the calibration interval was taken as the study duration minus 1 day.

Onboard stability was performed such that >80% of the reagent pack was consumed over the duration of the study. Data was analyzed by plotting and performing a linear regression of the delta values (Y-axis) versus test day (X-axis). If the regression slope was statistically significant ( $p < 0.05$ ), onboard stability for that sample was taken as the time at which the two-sided 90% confidence interval of the regression line intersected with the allowable drift-acceptance criterion. If the regression slope was not significant ( $p \geq 0.05$ ), onboard stability was taken as the study duration minus 1 day.

## Results

### Method comparison

Evaluation of 129 samples using the ANDRO assay on the ADVIA Centaur XP system and LC-MS/MS Androstenedione demonstrated a slope of 1.06, intercept of  $-0.08$  ng/mL, and  $r$  of 0.966.



**Figure 2.** Method comparison of the ADVIA Centaur ANDRO Assay versus LC-MS/MS Androstenedione via Passing-Bablok regression.

Agreement of the assays may vary depending on the study design, comparative assay, and sample population used. Assay results obtained at individual laboratories may vary from the data presented.

### Specimen equivalence

Evaluation of 63 matched serum, EDTA plasma, and lithium heparin plasma samples using the ANDRO assay on the ADVIA Centaur XP system demonstrated similar performance of lithium heparin and EDTA plasma matrices versus serum with slope, intercept, and  $r$  values as shown in Table 1.

**Table 1.** Evaluation of specimen equivalence for the ADVIA Centaur ANDRO Assay.

Sample Types	n	Slope	Y-intercept (ng/mL)	r
Lithium heparin plasma vs. serum	63	1.00	0.01	0.998
EDTA plasma vs. serum	63	1.02	0.10	0.998

## Precision

Precision evaluation via 20-day ANOVA using the ANDRO assay on the ADVIA Centaur XP system demonstrated maximum repeatability and within-lab %CVs (with 95% confidence) of 5.0% and 7.2%, respectively.

**Table 2.** Evaluation of precision for the ADVIA Centaur ANDRO Assay.\*

Sample ID	Grand Mean (ng/mL)	Repeatability			Within Lab		
		SD	CV (%)	95% UCL <sup>a</sup>	SD	CV (%)	95% UCL <sup>a</sup>
Low Calibrator	0.69	0.025	3.6	4.4	0.036	5.3	6.3
High Calibrator	5.36	0.152	2.8	3.5	0.264	4.9	6.0
QC Level 2	1.07	0.031	2.9	3.6	0.043	4.0	4.8
QC Level 3	2.02	0.057	2.8	3.5	0.079	3.9	4.7
Serum 1	0.54	0.018	3.4	4.1	0.028	5.2	6.2
Serum 2	1.07	0.029	2.7	3.3	0.042	3.9	4.7
Serum 3	2.65	0.066	2.5	3.1	0.104	3.9	4.6
Serum 4	5.62	0.218	3.9	4.8	0.298	5.3	6.2
Lithium Heparin Plasma	0.45	0.018	4.1	5.0	0.027	6.1	7.2

a. UCL: upper confidence limit.

\*Representative data from internal studies.

## Interference

Ten of the 11 potential endogenous and exogenous interferents evaluated demonstrated  $\leq 10\%$  interference in the ANDRO assay on the ADVIA Centaur XP system. Biotin interference was  $\leq 10\%$  at biotin concentrations  $\leq 635$  ng/mL.

**Table 3.** Evaluation of interference for the ADVIA Centaur ANDRO Assay.

Compound	Concentration Tested	% Interference	
		0.80–1.20 ng/mL ANDRO	2.00–3.00 ng/mL ANDRO
Hemoglobin	2 g/L	–0.9	0.3
Lipemia (INTRALIPID)	1000 mg/dL	–1.2	–3.0
Bilirubin (conjugated)	0.2 g/L	–0.4	–1.0
Bilirubin (unconjugated)	0.2 g/L	1.2	2.3
Silwet L720	0.03 mg/mL	–3.0	–2.7
Cholesterol	5 g/L	4.2	–3.0
Human gamma globulin	60 g/L	0.0	2.7
Human serum albumin	60 g/L	6.0	–2.2
Total protein	120 g/L	2.0	–6.1
Rheumatoid factor	1000 IU/mL	9.2	–2.6

### Cross-reactivity

Over 40 endogenous and exogenous potential cross-reactants were evaluated using the ANDRO assay on the ADVIA Centaur XP system. Of these, only the aromatase inhibitors exemestane and formestane demonstrated >1% cross-reactivity. The potential cross-reactants evaluated included:

Adrenosterone	Dutasteride	11-Ketotestosterone
Aldosterone	Epitestosterone	Leuprolide acetate
5 $\beta$ -Androstan-3 $\alpha$ , 17 $\beta$ -diol	Estradiol-17 $\beta$	Metformin
$\Delta$ 4-Androsten-11 $\beta$ -ol-3, 17-dione	Estriol	Norethindrone
Androsterone	Estrone	Oxandrolone
Canrenone	Etiocholanone	Prednisone
Cholesterol	Exemestane	Pregnenolone
Corticosterone	Finasteride	Progesterone
Cortisol	Fludrocortisone acetate	Salmeterol xinafoate
Cortisone	Fluticasone propionate	Spironolactone
Deoxycorticosterone	Formestane	Testosterone
Dexamethasone	Fulvestrant	17 $\alpha$ -Thiomethyl spironolactone
DHEA	Glycyrrhetic acid	Triptorelin
DHEA-SO <sub>4</sub>	Glycyrrhizic acid	
5 $\alpha$ -Dihydrotestosterone	17 $\alpha$ -Hydroxyprogesterone	

### Calibration interval and onboard stability

Evaluation of calibration interval and onboard stability using the ANDRO assay on the ADVIA Centaur XP system demonstrated a calibration interval and onboard stability of 35 days.

**Table 4.** Evaluation of calibration interval for the ADVIA Centaur ANDRO Assay.

	Low Calibrator	High Calibrator	QC Level 2	Serum	Lithium Heparin Plasma
p-value of fit	0.584	0.119	0.574	0.496	0.703
Days of stability	35	35	35	35	35

**Table 5.** Evaluation of onboard stability for the ADVIA Centaur ANDRO Assay.

	Low Calibrator	High Calibrator	QC Level 2	Serum	Lithium Heparin Plasma
p-value of fit	0.489	0.284	0.823	0.607	0.772
Days of stability	35	35	35	35	35

## Conclusion

The performance of the ADVIA Centaur ANDRO Assay has been evaluated, and the results demonstrate an accurate and precise method for the measurement of androstenedione in human serum and plasma. The assay correlates well with LC-MS/MS.

At Siemens Healthineers, our purpose is to enable healthcare providers to increase value by empowering them on their journey toward expanding precision medicine, transforming care delivery, and improving patient experience, all made possible by digitalizing healthcare.

An estimated 5 million patients globally benefit every day from our innovative technologies and services in the areas of diagnostic and therapeutic imaging, laboratory diagnostics, and molecular medicine, as well as digital health and enterprise services.

We are a leading medical technology company with over 120 years of experience and 18,000 patents globally. Through the dedication of more than 50,000 colleagues in 75 countries, we will continue to innovate and shape the future of healthcare.

ADVIA Centaur and all associated marks are trademarks of Siemens Healthcare Diagnostics Inc., or its affiliates. All other trademarks and brands are the property of their respective owners.

Product availability may vary from country to country and is subject to varying regulatory requirements. Please contact your local representative for availability.

#### References:

1. Payne AH, Hales DB. Overview of steroidogenic enzymes in the pathway from cholesterol to active steroid hormones. *Endocr Rev.* 2004;25(6):947-70.
2. Speiser PW, Azziz R, Baskin LS, et al. Congenital adrenal hyperplasia due to steroid 21-hydroxylase deficiency: an Endocrine Society clinical practice guideline. *J Clin Endocrinol Metab.* 2010;95(9):4133-60.
3. Rodin A, Thakkar H, Taylor N, et al. Hyperandrogenism in polycystic ovarian syndrome. Evidence of dysregulation of 11 $\beta$ -hydroxysteroid dehydrogenase. *N Engl J Med.* 1994;330:460-5.
4. Georgopoulos NA, Papadakis E, Armeni AK, et al. Elevated serum androstenedione is associated with a more severe phenotype in women with polycystic ovarian syndrome (PCOS). *Hormones (Athens).* 2014;13(2):213-21.
5. O'Reilly MW, Taylor AE, Crabtree NJ, et al. Hyperandrogenemia predicts metabolic phenotype in polycystic ovarian syndrome: the utility of serum androstenedione. *J Clin Endocrinol Metab.* 2014;99(3):1027-36.
6. Fox R, Corrigan E, Thomas PA, et al. The diagnosis of polycystic ovaries in women with oligo-amenorrhoea: predictive power of endocrine tests. *Clin Endocrinol (Oxf).* 1991; 34(2):127-31.
7. Summers RH, Herold DA, Seely BL. Hormonal and genetic analysis of a patient with congenital adrenal hyperplasia. *Clin Chem.* 1996;42(9):1483-7.
8. Debono M, Mallappa A, Gounden V, et al. Hormonal circadian rhythms in patients with congenital adrenal hyperplasia: identifying optimal monitoring times and novel disease biomarkers. *Eur J Endocrinol.* 2015;173(6):727-37.
9. Otten BJ, Wellen JJ, Rijken JC, et al. Salivary and plasma androstenedione and 17-hydroxyprogesterone levels in congenital adrenal hyperplasia. *J Clin Endocrinol Metab.* 1983;57(6):1150-4.
10. Lizneva D, Gavrilova-Jordan L, Walker W, et al. Androgen excess: investigations and management. *Best Pract Res Clin Obstet Gynaecol.* 2016;37:98-118.
11. Juniarto AZ, Goossens K, Setyawati BA, et al. Correlation between androstenedione and 17-hydroxyprogesterone levels in the saliva and plasma of patients with congenital adrenal hyperplasia. *Singapore Med J.* 2011;52(11):810-3.
12. Utriainen P, Laakso J, Liimatta J, et al. Premature adrenarche-a common condition with variable presentation. *Horm Res Paediatr.* 2015;83(4):221-31.

---

#### Siemens Healthineers Headquarters

Siemens Healthcare GmbH  
Henkestr. 127  
91052 Erlangen, Germany  
Phone: +49 9131 84-0  
siemens-healthineers.com

#### Published by

Siemens Healthcare Diagnostics Inc.  
Laboratory Diagnostics  
511 Benedict Avenue  
Tarrytown, NY 10591-5005  
USA  
Phone: +1 914-631-8000